Clinical trial readout dates for Halozyme Therapeutics Inc., compiled from
ClinicalTrials.gov, alongside the SEC filings where results are announced.
The next expected readout is March 2028.
Halozyme Therapeutics Inc. reported $1.03B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-05). It reported net income of $247M for that quarter.
Recent SEC filings
8-KResults of Operations — earnings, may carry pipeline updates